Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: safety, efficacy, biomarker, and pharmacokinetics – CheckMate 908
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Therapeutic options are limited in pediatric CNS malignancies. CheckMate 908 (NCT03130959) is an open-label, sequential-arm, phase 1b/2 study investigating nivolumab (NIVO) and NIVO + ipilimumab (IPI) in pediatric patients with high-grade CNS malignancies. METHODS: Patients (N = 166) in 5 cohorts received NIVO 3 mg/kg every 2 weeks (Q2W) or NIVO 3 mg/kg + IPI 1 mg/kg every 3 weeks (4 doses) followed by NIVO 3 mg/kg Q2W. Primary endpoints included overall survival (OS; newly diagnosed diffuse intrinsic pontine glioma [DIPG]) and progression-free survival (PFS; other recurrent/progressive or relapsed/resistant CNS cohorts). Secondary endpoints included other efficacy metrics and safety. Exploratory endpoints included pharmacokinetics and biomarker analyses. RESULTS: As of January 13, 2021, median OS (80% CI) was 11.7 (10.3-16.5) and 10.8 (9.1-15.8) months with NIVO and NIVO + IPI, respectively, in newly diagnosed DIPG. Median PFS (80% CI) with NIVO and NIVO + IPI was 1.7 (1.4-2.7) and 1.3 (1.2-1.5) months, respectively, in recurrent/progressive high-grade glioma; 1.4 (1.2-1.4) and 2.8 (1.5-4.5) months in relapsed/resistant medulloblastoma; and 1.4 (1.4-2.6) and 4.6 (1.4-5.4) months in relapsed/resistant ependymoma. In patients with other recurrent/progressive CNS tumors, median PFS (95% CI) was 1.2 (1.1-1.3) and 1.6 (1.3-3.5) months, respectively. Grade 3/4 treatment-related adverse-event rates were 14.1% (NIVO) and 27.2% (NIVO + IPI). NIVO and IPI first-dose trough concentrations were lower in youngest and lowest-weight patients. Baseline tumor programmed death ligand 1 expression was not associated with survival. CONCLUSIONS: NIVO ± IPI did not demonstrate clinical benefit relative to historical data. The overall safety profiles were manageable with no new safety signals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several phase I/II studies of ICI monotherapies (ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab) and combination regimens (nivolumab plus ipilimumab) have been conducted in pediatric populations, but limited antitumor activity has been observed, with objective response rates ranging from 0% to 5.9% for children with a solid tumor, including sarcoma.”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ICI combination of nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) was also evaluated in patients with high-grade central nervous system tumors (ages 0.5–21 years) in the CheckMate 908 study, which reported no improvement in PFS and OS outcomes for patients with newly diagnosed diffuse intrinsic pontine glioma and relapsed/refractory central nervous system malignancies compared with historical”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · cited 1×
“Prior studies of PD-1 inhibitors suggest TMB as an 42–45 46 a separate cohort for this patient population was not included in this study.”
Molecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936 · cited 1×
“28,29 c .”
Self-citationThe role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382
The whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112 · cited 1×
“28,29 c .”
Self-citationBrain and other central nervous system tumor statistics, 2021
Miller, K. D., Ostrom, Q. T., Kruchko, C., Patil, N., Tihan, T., Cioffi, G., Fuchs, H. E., Waite, K. A., Jemal, A., Siegel, R. L., et al. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21693 · Cited by 997
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Self-citation(2015) · European Journal of Haematology · doi:10.1111/ejh.12636 · Cited by 780
Medulloblastomics: the end of the beginning
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y.-J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3410 · Cited by 663
Research works printed but not linked: 1
- Yervoy (ipilimumab), 2021, Prescribing Information
Cited by
Hargrave, D., Marshall, L. V., André, N., Krystal, J., Ladle, B. H., Robbins, K. A., Hois, S., Armstrong, J., & Donegan, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1680081 · Cited by 1
Self-citation
Metadata
- Authors
- Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., Bartels, U., Gajjar, A., Howell, L., Warad, D., Pacius, M., Tam, R., Wang, Y., Zhu, L., & Cohen, K.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Université Paris Cité (FR)
- Morgan Adams Foundation (US)
- Great Ormond Street Hospital (GB)
- Department of Pediatric Hematology-Oncology, Hospital Infantil Universitario Niño Jesús , Madrid , Spain
- Département de Radiothérapie, Hopital pour Enfants de la Timone, Department of Pediatric Hematology and Oncology, AP-HM and Centre de Recherche en Cancérologie de Marseille, Aix Marseille Université , Marseille , France
- Royal Children's Hospital (AU)
- Children's Health Queensland Hospital and Health Service (AU)
- Universitätsklinikum Würzburg (DE)
- University of Florida (US)
- Hospital for Sick Children (CA)
- St. Jude Children's Research Hospital (US)
- Alder Hey Children's Hospital (GB)
- Bristol-Myers Squibb (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Dunkel, Ira J
- ORCID
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-02-20
- Volume
- 25
- Issue
- 8
- Pages
- 1530-1545
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC10398811
- OpenAlex
- W4321372568
- Cited by
- 73
- References
- 49
- Citations by year
- 2026: 24 · 2025: 26 · 2024: 16 · 2023: 6
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Neuro-Oncology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health
- National Cancer Institute (P30 CA008748)
- National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- nivolumab, ipilimumab, immune checkpoint inhibitors, pediatric central nervous system tumors, diffuse intrinsic pontine glioma, medulloblastoma, ependymoma, recurrent high-grade glioma, overall survival, progression-free survival, treatment-related adverse events, pharmacokinetics, biomarkers, immune-related adverse events, sequential immunotherapy, PD-1/PD-L1 blockade, CTLA-4 blockade, brain tumor immunotherapy
- MeSH terms
- Ipilimumab, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Child, Humans, Neoplasms, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: safety, efficacy, biomarker, and pharmacokinetics – CheckMate 908. https://app.cochat.ai/papers/10.1093/neuonc/noad031
- The paper
- Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., Bartels, U., Gajjar, A., Howell, L., Warad, D., Pacius, M., Tam, R., Wang, Y., Zhu, L., & Cohen, K. (2023). Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: safety, efficacy, biomarker, and pharmacokinetics – CheckMate 908. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.